Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Mast Therapeutics (MSTX) Offers Business Update; Phase 3 EPIC Enrollment Surpasses 90% Mark
January 7, 2016 8:06 AM ESTMast Therapeutics, Inc. (NYSE: MSTX) provided a business update.
The Company reported that patient enrollment in the pivotal Phase 3 "EPIC" study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease recently surpassed the 90% mark. The Company expects to complete patient enrollment in February. Consistent with prior guidance, the Company expects to report top-line results in the second quarter of... More